Loading...
•
Sep 30, 2022
Bio-Techne Q1 2023 Earnings Report
Bio-Techne's Q1 2023 earnings were released, showing revenue growth and strong performance in the Diagnostics and Genomics segment.
Key Takeaways
Bio-Techne Corporation reported a 5% increase in net sales to $269.7 million for the first quarter of fiscal year 2023. The Diagnostics and Genomics segment showed significant organic growth, offsetting challenges in the Protein Sciences segment. GAAP EPS was $2.21, while adjusted EPS was $1.78.
Organic revenue increased by 7% to $269.7 million.
GAAP EPS was $2.21, up from $1.69 in the previous year.
Diagnostics and Genomics segment achieved 17% organic growth.
Operating cash flow increased by 16% to $56.1 million.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income